Published in

Elsevier, European Journal of Cancer, (172), p. 231-233, 2022

DOI: 10.1016/j.ejca.2022.05.045

Links

Tools

Export citation

Search in Google Scholar

Response to letter entitled re: UGT1A1 genotype-guided dosing of irinotecan: A prospective safety and cost analysis in poor metaboliser patients

This paper was not found in any repository, but could be made available legally by the author.
This paper was not found in any repository, but could be made available legally by the author.

Full text: Unavailable

Green circle
Preprint: archiving allowed
Orange circle
Postprint: archiving restricted
Red circle
Published version: archiving forbidden
Data provided by SHERPA/RoMEO